Recent advances in medicinal chemistry, which are involved with design, chemical synthesis, and development for market of pharmaceutical agents or bioactive molecules, have identified inhibitors targeting G12C KRAS variants, which are mainly found in lung adenocarcinomas.7 Our results suggest that in patients with ICC, the G12D KRAS variant has the greatest prevalence, whereas the G12V KRAS variant is the strongest prognostic determinant and therefore probably the most oncogenic of the KRAS variants. The gene discussed is KRAS; the disease is lung adenocarcinoma.